![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal spray) in China (including Chinese mainland, Hong Kong and Macao SAR, Taiwan region).
Lead Product(s): Budesonide
Therapeutic Area: Immunology Product Name: Budesolv
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Marinomed Biotech
Deal Size: $22.0 million Upfront Cash: $2.0 million
Deal Type: Licensing Agreement October 19, 2021